Literature DB >> 29254982

Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? CD8 T-Cell Vaccines: To B or Not to B?

Lalit K Beura1,2, Stephen C Jameson2,3, David Masopust1,2.   

Abstract

Although CD8 T-cell vaccines do not have the record of success of humoral-mediated vaccines, they do not receive the same degree of effort. Many diseases, including malaria, tuberculosis, and acquired immune deficiency syndrome (AIDS) have not yielded to vaccines, and intrinsic barriers may impede approaches limited solely to generating antibodies. Moreover, population growth and modernization are driving an increased pace of new emerging global health threats (human immunodeficiency virus [HIV] is a recent example), which will create unpredictable challenges for vaccinologists. Vaccine-elicited CD8 T cells may contribute to protective modalities, although their development will require a more thorough understanding of CD8 T-cell biology, practices for manufacturing and delivering CD8 T-cell-eliciting vectors that have acceptable safety profiles, and, ultimately, the political will and faith of those that make vaccine research funding decisions.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29254982     DOI: 10.1101/cshperspect.a028910

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  3 in total

1.  Protein vaccine NVX-CoV2373 elicits functional T cell immunity.

Authors:  Pengcheng Zhou
Journal:  J Clin Invest       Date:  2022-10-03       Impact factor: 19.456

2.  NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses.

Authors:  Carolyn Rydyznski Moderbacher; Christina Kim; Jose Mateus; Joyce Plested; Mingzhu Zhu; Shane Cloney-Clark; Daniela Weiskopf; Alessandro Sette; Louis Fries; Gregory Glenn; Shane Crotty
Journal:  J Clin Invest       Date:  2022-10-03       Impact factor: 19.456

3.  Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans.

Authors:  Stefania Capone; Anthony Brown; Felicity Hartnell; Mariarosaria Del Sorbo; Cinzia Traboni; Ventzislav Vassilev; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori; Paul Klenerman; Eleanor Barnes; Leo Swadling
Journal:  NPJ Vaccines       Date:  2020-10-12       Impact factor: 9.399

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.